| 05/04/2026 3:41 PM | CRISPR Therapeutics (1674416) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/04/2026 3:48 PM | CRISPR Therapeutics (1674416) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/30/2026 11:41 AM | ARK Investment Management LLC (1697748) Filed by CRISPR Therapeutics (1674416) Subject | Form SCHEDULE 13G/A | |
| 04/21/2026 7:11 AM | CRISPR Therapeutics (1674416) Filer | Form DEFA14A | |
| 04/21/2026 7:18 AM | CRISPR Therapeutics (1674416) Filer | Form ARS | |
| 04/21/2026 7:05 AM | CRISPR Therapeutics (1674416) Filer | Form DEF 14A | |
| 04/02/2026 3:23 PM | CRISPR Therapeutics (1674416) Filer | Form PRE 14A | |
| 03/24/2026 4:36 PM | CRISPR Therapeutics (1674416) Issuer Patel Naimish (2021679) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/24/2026 4:37 PM | CRISPR Therapeutics (1674416) Issuer Prasad Raju (1968317) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/24/2026 4:37 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/24/2026 4:38 PM | CRISPR Therapeutics (1674416) Issuer KASINGER JAMES R. (1708172) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for CRSP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 03/17/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/17/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer KASINGER JAMES R. (1708172) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/17/2026 4:37 PM | CRISPR Therapeutics (1674416) Issuer Prasad Raju (1968317) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/17/2026 4:37 PM | CRISPR Therapeutics (1674416) Issuer Patel Naimish (2021679) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/12/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/12/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer KASINGER JAMES R. (1708172) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/11/2026 6:07 AM | CRISPR Therapeutics (1674416) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/20/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer KASINGER JAMES R. (1708172) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/20/2026 4:36 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 11:06 AM | CRISPR Therapeutics (1674416) Subject ORBIS INVESTMENT MANAGEMENT LTD (940594) Filed by | Form SCHEDULE 13G/A | |
| 01/27/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer Patel Naimish (2021679) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/26/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer Prasad Raju (1968317) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/22/2026 4:55 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/22/2026 4:15 PM | CRISPR Therapeutics (1674416) Subject Kulkarni Samarth (1682019) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/22/2026 3:03 PM | CRISPR Therapeutics (1674416) Subject Prasad Raju (1968317) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/20/2026 4:11 PM | CRISPR Therapeutics (1674416) Subject Kulkarni Samarth (1682019) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/12/2026 7:44 AM | CRISPR Therapeutics (1674416) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/08/2026 4:35 PM | CRISPR Therapeutics (1674416) Issuer Prasad Raju (1968317) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 4:11 PM | CRISPR Therapeutics (1674416) Subject Prasad Raju (1968317) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/23/2025 4:33 PM | CRISPR Therapeutics (1674416) Issuer Prasad Raju (1968317) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/22/2025 4:35 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/22/2025 3:20 PM | CRISPR Therapeutics (1674416) Subject Prasad Raju (1968317) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/14/2025 11:26 AM | CRISPR Therapeutics (1674416) Subject ORBIS INVESTMENT MANAGEMENT LTD (940594) Filed by | Form SCHEDULE 13G | |
| 11/10/2025 7:10 AM | CRISPR Therapeutics (1674416) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/10/2025 7:15 AM | CRISPR Therapeutics (1674416) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/04/2025 3:48 PM | ARK Investment Management LLC (1697748) Filed by CRISPR Therapeutics (1674416) Subject | Form SCHEDULE 13G/A | |
| 10/20/2025 4:35 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/15/2025 4:35 PM | CRISPR Therapeutics (1674416) Issuer KASINGER JAMES R. (1708172) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/15/2025 4:35 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/15/2025 3:18 PM | CRISPR Therapeutics (1674416) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
|
| 10/15/2025 3:10 PM | CRISPR Therapeutics (1674416) Filer | Form 424B5 | |
| 10/03/2025 4:36 PM | CRISPR Therapeutics (1674416) Issuer Prasad Raju (1968317) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/03/2025 4:36 PM | CRISPR Therapeutics (1674416) Issuer KASINGER JAMES R. (1708172) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/03/2025 4:37 PM | CRISPR Therapeutics (1674416) Issuer Patel Naimish (2021679) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/03/2025 4:38 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/19/2025 4:42 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/19/2025 3:30 PM | CRISPR Therapeutics (1674416) Issuer Kulkarni Samarth (1682019) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/04/2025 3:30 PM | CRISPR Therapeutics (1674416) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/17/2025 6:44 PM | BlackRock, Inc. (2012383) Filed by CRISPR Therapeutics (1674416) Subject | Form SCHEDULE 13G | |
| 06/26/2025 6:08 AM | CRISPR Therapeutics (1674416) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/10/2025 4:31 PM | CRISPR Therapeutics (1674416) Issuer Morrison Briggs (1654430) Reporting | Form 3/A | |
| 06/06/2025 4:38 PM | Behbahani Ali (1613867) Reporting CRISPR Therapeutics (1674416) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:47 PM | CRISPR Therapeutics (1674416) Issuer George Simeon (1595117) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:20 PM | CRISPR Therapeutics (1674416) Issuer Morrison Briggs (1654430) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer High Katherine A (1631248) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer Fardis Maria (1559231) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer Mahatme Sandesh (1511034) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer Greene John (1610732) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer Fleming Harold Edward (1857250) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer Rommel Christian (2022449) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer Treco Douglas A (1688192) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 4:30 PM | CRISPR Therapeutics (1674416) Issuer Morrison Briggs (1654430) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2025 8:45 PM | CRISPR Therapeutics (1674416) Issuer Patel Naimish (2021679) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2025 8:45 PM | CRISPR Therapeutics (1674416) Issuer Prasad Raju (1968317) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2025 9:52 AM | ARK Investment Management LLC (1697748) Filed by CRISPR Therapeutics (1674416) Subject | Form SCHEDULE 13G/A | |
| 05/13/2025 4:53 PM | Capital International Investors (1562230) Filed by CRISPR Therapeutics (1674416) Subject | Form SCHEDULE 13G/A | |